Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Buy” by Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given an average rating of “Buy” by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $13.38.

A number of brokerages have weighed in on CMPX. Piper Sandler assumed coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price on the stock. Guggenheim restated a “buy” rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. Leerink Partners upgraded shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. Finally, D. Boral Capital restated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st.

Compass Therapeutics Trading Down 9.0 %

Shares of NASDAQ CMPX opened at $1.46 on Wednesday. The stock has a fifty day simple moving average of $2.76 and a two-hundred day simple moving average of $2.11. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The firm has a market cap of $201.89 million, a price-to-earnings ratio of -3.95 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Analysts forecast that Compass Therapeutics will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CMPX. Barclays PLC boosted its position in shares of Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares in the last quarter. SG Americas Securities LLC raised its stake in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after buying an additional 356,352 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after acquiring an additional 19,095 shares in the last quarter. Bleakley Financial Group LLC grew its stake in shares of Compass Therapeutics by 250.7% during the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock worth $58,000 after acquiring an additional 28,589 shares during the last quarter. Finally, Intech Investment Management LLC increased its holdings in shares of Compass Therapeutics by 218.7% during the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock valued at $75,000 after acquiring an additional 35,632 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.